Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Remifentanil provides effective analgesia during invasive mechanical ventilation (IMV), but its utility is limited by opioid-related adverse events. Oliceridine, a G protein-biased μ-opioid receptor agonist, may decouple analgesia from these effects, but lacks evidence in critically ill patients. This multicentre, assessor- and patient-blinded, non-inferiority randomised controlled trial was conducted across 19 intensive care units (ICUs) in China. Adults receiving IMV were randomised 1:1 to oliceridine or remifentanil, titrated to a Critical-Care Pain Observation Tool score below 3. The primary endpoint was time in target analgesic range (TTR; non-inferiority margin −10%). Of 307 randomised patients, 304 comprised the modified intention-to-treat population (151 oliceridine, 153 remifentanil). Median TTR was 96.0% versus 92.3% (absolute difference 3.7%, 95% CI −0.3–5.7%). Oliceridine was associated with fewer mild-to-moderate adverse drug reactions (ADRs), occurring at 15.9 versus 22.2 events per 100 patient-days (IRR 0.72, 95% CI 0.52–1.00, P = 0.049), and a lower rate of respiratory depression during the study period (0% vs. 4.6%, P = 0.015). Post-extubation respiratory depression (0% vs. 7.9%, P = 0.005) and analgesic-sedation costs were both lower with oliceridine. IMV duration, ICU stay, and 28-day mortality did not differ. Subgroup analyses identified a nominal ADR benefit in patients with Acute Physiology and Chronic Health Evaluation II > 17 and a larger nominal TTR difference in those without acute respiratory distress syndrome. Oliceridine provides non-inferior analgesia to remifentanil with a more favourable respiratory safety profile and lower costs in critically ill adults. ClinicalTrials.gov NCT06454292 (registered June 11, 2024). In this multicentre randomised trial of 304 mechanically ventilated critically ill adults, oliceridine provided non-inferior analgesia to remifentanil with no post-extubation respiratory depression events (0% vs 7.9%) and numerically fewer mild-to-moderate adverse drug reactions and lower analgesic-sedation expenditure, supporting oliceridine as a promising analgesic alternative where respiratory safety during ventilator liberation is paramount.
Source: Intensive Care Medicine
Authors: Sen Lu, Jing-chao Luo, Qiang Li, Xian-ying Lei, Xue-feng Ding, Qiong-lan Dong, Qiong-hua Hu, Wen-tuo Zhu, Xue Zhang, Li-li Duan, Sheng Lv, Qi-fang Ran, Li Ma, Chuan Guo, Jian-jun Dong, Yu-qi Yang, Li Xu, Jin Yang, Jun Wang, Li-fei Qiu, Ben-cai Jing, Feng-juan Jia, Li Zhang, Qi-bing Tang, Miguel Ibarra-Estrada, Ming-hao Luo, Chun Pan, Xiao-bo Huang, Ignacio Martin-Loeches
Institutions: University of Electronic Science and Technology of China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Southwest Medical University, Affiliated Hospital of Southwest Medical University, Affiliated Hospital of North Sichuan Medical College, Mianyang Third People's Hospital, Sichuan University, Chengdu Second People's Hospital, The First People's Hospital of Neijiang, Panzhihua Central Hospital, First Affiliated Hospital of Chengdu Medical College, The First People's Hospital of Guangyuan, Zigong First People's Hospital, Third People's Hospital of Chengdu, Universidad de Guadalajara, Hospital Civil de Guadalajara, Instituto Jalisciense de Cancerología, Cambridge University Hospitals NHS Foundation Trust, University of Oxford, Addenbrooke's Hospital, Trinity College Dublin, St. James's Hospital
Language: English
Subfield: Anesthesiology and Pain Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W7164578746
